ID   KMS-28PE
AC   CVCL_2995
SY   KMS-28-PE; KMS28PE; Kawasaki Medical School-28-Pleural Effusion
DR   EFO; EFO_0006618
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_2995
DR   CGH-DB; 33-1
DR   CGH-DB; 9144-4
DR   Cell_Model_Passport; SIDM01656
DR   Cell_Model_Passport; SIDM01797
DR   Cosmic; 2081428
DR   Cosmic; 2081440
DR   Cosmic; 2367289
DR   DepMap; ACH-001541
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM621589
DR   JCRB; JCRB1191
DR   JCRB; NIHS0489
DR   Lonza; 1429
DR   PharmacoDB; KMS28PE_771_2019
DR   Progenetix; CVCL_2995
DR   Wikidata; Q54900178
RX   CelloPub=CLPUB00604;
RX   PubMed=15215163;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   HLA typing: A*24:02,24:02; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly105Arg (c.313G>C); ClinVar=VCV000406574; Zygosity=Homozygous (DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: JCRB; NIHS0489; true.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DepMap; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 14,15
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 14
ST   D7S820: 8,11
ST   D8S1179: 10,11
ST   FGA: 20,23
ST   Penta D: 9,11
ST   Penta E: 12,15
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2994 ! KMS-28BM
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//